Next-Generation Antibody Therapeutics Market Analysis

Next-Generation Antibody Therapeutics Industry Insights

Therapeutic Area Analysis

The oncology category accounts for the largest revenue share, of approximately 90%, in 2024, and it is expected to showcase the highest CAGR, of around 8%, in the forecast period. This is because of the rising incidence of breast cancer, colorectal cancer, prostate cancer, brain cancer, and lung cancer, where antibody therapeutics offer benefits throughout the therapies.

These treatments provide enhanced efficiency by targeting cancer cells and ensuring optimal damage is caused to healthy tissues, resulting in better results and fewer side-effects. In addition, the availability of various next-generation antibody therapeutics, such as Kadcyla, ADCETRIS, and Poteligeo, for the treatment of cancers including breast cancer, lymphoma, and melanoma has intensified the domain revenue.

The therapeutic areas analyzed here are:

• Oncology (Largest and Fastest-Growing Category)
• Autoimmune/Inflammatory Diseases
• Others

Technology Analysis

The ADC category dominates the market in 2024, and the same category is set to register the highest CAGR, of around 10%, in the forecast period. The category growth is mainly due to the high demand for antibody-based cancer therapy, coupled with the rising incidence of breast cancer, technological advancements, and a rapid increase in the number of these conjugates under clinical trials.

Additionally, the adoption of the cleavable linker technology is expected to provide significant growth opportunities to the eponymous category, due to its high stability in the bloodstream for a prolonged duration and effective release of cytotoxins from ADCs at the targeted tumor site. In developing countries, such as China, the technology is extensively being used for the treatment of relapsing systemic anaplastic large-cell lymphoma and relapsing Hodgkin's lymphoma.

Several key players, such as Janssen Pharmaceutical Companies, ADC Therapeutics, Seagen Inc., and AstraZeneca plc, are actively involved in collaborations, to enhance their revenue and customer base. For instance, in April 2024, the therapeutic research branch of Caris Life Sciences, Caris Discovery signed an agreement with Merck KGaA to facilitate the detection and development of ADCs against cancer. Under this agreement, USD 1.4 billion has been allocated for research funding and an international license to Merck to manufacture ADC therapies and provide an orthogonal multi-omics approach to eliminate tumors.

Furthermore, the increase in pharma funding by both private as well as public organizations, for the production of novel ADCs, is expected to drive the next-generation antibody therapeutics market growth in the forecast period. In recent years, there has been a swift increase in the incidence of multiple myeloma all over the world, which is driving the demand for ADCs. Additionally, the several initiatives taken by federal agencies in support of these therapeutic candidates are expected to boost the revenue for pharma and biopharma firms.

The technologies analyzed here are:

• Antibody–Drug Conjugates (ADCs) (Largest and Fastest-Growing Category)
• Bispecific Antibodies
• Fc-Engineered Antibodies
• Antibody Fragments and Antibody-Like Proteins
• Biosimilar Antibodies